Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST ® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 – – KPL-1161 Phase 1 trial planned